- Report
- June 2026
- 205 Pages
Global
From €4513EUR$4,799USD£3,765GBP
- Report
- July 2026
- 517 Pages
Global
From €4655EUR$4,950USD£3,884GBP
- Report
- April 2026
- 240 Pages
Global
From €3104EUR$3,300USD£2,589GBP
- Report
- January 2026
- 240 Pages
Global
From €2351EUR$2,500USD£1,961GBP
- Report
- June 2026
- 222 Pages
Global
From €4513EUR$4,799USD£3,765GBP
- Report
- October 2026
- 245 Pages
Global
From €3927EUR$4,175USD£3,276GBP
- Report
- September 2026
- 310 Pages
Global
From €3927EUR$4,175USD£3,276GBP
- Report
- June 2026
- 290 Pages
Global
From €3903EUR$4,150USD£3,256GBP
- Report
- March 2026
- 288 Pages
Global
From €3903EUR$4,150USD£3,256GBP
- Report
- March 2026
- 320 Pages
Global
From €3903EUR$4,150USD£3,256GBP
- Report
- March 2026
- 316 Pages
Global
From €3903EUR$4,150USD£3,256GBP
- Report
- June 2026
- 295 Pages
Global
From €4655EUR$4,950USD£3,884GBP
- Report
- February 2026
- 250 Pages
Global
From €4223EUR$4,490USD£3,523GBP
- Report
- June 2026
- 200 Pages
Global
From €2812EUR$2,990USD£2,346GBP
- Report
- October 2026
- 367 Pages
Global
From €3927EUR$4,175USD£3,276GBP
- Report
- September 2026
- 150 Pages
Global
From €5596EUR$5,950USD£4,668GBP
- Report
- August 2026
- 120 Pages
Global
From €5596EUR$5,950USD£4,668GBP
- Report
- May 2026
- 150 Pages
Global
From €5596EUR$5,950USD£4,668GBP
- Report
- April 2026
- 120 Pages
Global
From €5596EUR$5,950USD£4,668GBP
- Report
- July 2026
- 250 Pages
Global
From €4223EUR$4,490USD£3,523GBP

The Antibody Drug Conjugate (ADC) market is a subset of the biotechnology industry that focuses on the development of targeted therapies for cancer and other diseases. ADCs are composed of an antibody, a linker, and a cytotoxic drug. The antibody binds to a specific target on the surface of a cell, and the linker and drug are released when the ADC binds to the target. This allows for the delivery of a high dose of the drug to the target cell, while minimizing the damage to healthy cells.
ADCs have been used to treat a variety of cancers, including breast, ovarian, and non-small cell lung cancer. They have also been used to treat other diseases, such as autoimmune disorders and infectious diseases.
The ADC market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Seattle Genetics, ImmunoGen, Pfizer, Merck, and Novartis. Show Less Read more